Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (9996)	3/27/2007 11:40:55 AM
From: Iamarangerboy	Read Replies (1) \| Respond to of 10280

in regard to this new legal action.... Merck KGaA's Dey unit sued Sepracor Inc. in federal court in New York to prevent the introduction of Brovana, a medicine used to treat chronic bronchitis and emphysema. Marlborough-based Sepracor, maker of the Lunesta sleeping pill and Xopenex asthma treatment, plans to begin selling Brovana in the second quarter, according to the company's website. Dey says Brovana infringes its patent for a spray to open bronchial passages. A Sepracor spokeswoman didn't immediately return a phone call seeking comment. (Bloomberg) "its patent for a spray to open bronchial passages" there has got to be more to this patent than that... I remember clearly as a boy of 7... in the early 50's... spraying nebulized epinephrine into my lungs to stop asthma attacks.... how does someone get that patent!